

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of

Docket No: Q91144

Kazuo SHINMURA, et al.

Appln. No.: 10/555,068

Group Art Unit: Not Yet Assigned

Confirmation No.: 9169

Examiner: Not Yet Assigned

Filed: October 27, 2005

For:

CYTOKINE-INDUCING INSTRUMENT AND CYTOKINE-INDUCING METHOD

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.98

MAIL STOP AMENDMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with the duty of disclosure under 37 C.F.R. § 1.56, Applicant hereby notifies the U.S. Patent and Trademark Office of the documents which are listed on the attached PTO/SB/08 A & B (modified) form and/or listed herein and which the Examiner may deem material to patentability of the claims of the above-identified application.

One copy of each of the listed documents is submitted herewith, except for the following: U.S. patents and/or U.S. patent publications; and co-pending non-provisional U.S. applications filed after June 30, 2003. Also enclosed is a copy of the partial translation.

The present Information Disclosure Statement is being filed: (1) No later than three months from the application's filing date; (2) Before the mailing date of the first Office Action on the merits (whichever is later); or (3) Before the mailing date of the first Office Action after

INFORMATION DISCLOSURE STATEMENT

U.S. Appln. No.: 10/555,068

Page 2

filing a request for continued examination (RCE) under §1.114, and therefore, no Statement

under 37 C.F.R. § 1.97(e) or fee under 37 C.F.R. § 1.17(p) is required.

In compliance with the concise explanation requirement under 37 C.F.R. § 1.98(a)(3) for

foreign language documents, Applicant submits the following explanations:

Citations 1-3 are cited on page 1 of the specification where they are discussed in detail.

Citations 4 and 5 are cited in page 2 of the specification where they are discussed in

detail.

The submission of the listed documents is not intended as an admission that any such

document constitutes prior art against the claims of the present application. Applicant does not

waive any right to take any action that would be appropriate to antedate or otherwise remove any

listed document as a competent reference against the claims of the present application.

The USPTO is directed and authorized to charge all required fees, except for the Issue

Fee and the Publication Fee, to Deposit Account No. 19-4880. Please also credit any

overpayments to said Deposit Account.

Respectfully submitted,

Registration No.: 30,951

SUGHRUE MION, PLLC

Telephone: (202) 293-7060

Facsimile: (202) 293-7860

WASHINGTON OFFICE

23373

CUSTOMER NUMBER

Date: March 16, 2006

2

Substitute for Form 1449 A & B/PTO			Complete if Known			
			Application Number	10/555,068		
INFORMATION DISCLOSURE OVPE					Confirmation Number	9169
STATEMENT BY APPLICANT					Wiling Date	October 27, 2005
(use as many sheets as necessary) MAR 1 6 700				First Named Inventor	Kazuo SHINMURA	
(use	as many sheets a	s necessai	y) \3	Art Unit	Not Yet Assigned	
			/	Xaminer Name	Not Yet Assigned	
Sheet	1	of	1	MANGUART	Attorney Docket Number	Q91144

	U.S. PATENT DOCUMENTS							
Examiner	Cite	Document	Number	Publication Date				
Initials*	No.1	Number	Kind Code ² (if known)	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document			
		US						
		US						
		US						
		US						
	_	US						
		US						
		US						
		US						
		US						

FOREIGN PATENT DOCUMENTS							
Examiner	Cite	For	eign Patent Docu	ment	Publication Date	Name of Patentee or Applicant of Cited Document	
Initials*	No.1	Country Code ³	Number ⁴	Kind Code ⁵ (if known)	MM-DD-YYYY		Translation ⁶
						·	
							15.06.15.0

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city, and/or country where published.			
	1	Nobuyuki MIYASAKA, M.D., "Cytokines and their receptors" Clinical Immunology, Vol. 27, Suppl. 16, February 1995	Partial		
	2	Shinpei KASAKURA, M.D., Novel Interleukins (IL-19, IL-20, IL21), Clinical Immunology, Vol. 36, 39-44, (2001)			
	3	Shinpei KASAKURA, M.D. "IL-22~IL-27" Clinical Immunology, Vol. 39, 189-200, (2003)			
	4	Makoto YAMADA et al., "Studies on Antitumor Mechanism of Biological Response Modifier (BRM) and Significance of Responder Evaluated by Cytokine Production II. Analysis on Cytokine Production Stimulated by BRMs Using Peripheral Blood", Vol. 43, pp. 166-177, (1995)	Abstract		
	5	Akira Hayashi, "A New Trend of Cancer Immunotheraphy: BCG-CWS as a bridge between the innate immunity and the acquired", Molecular Medicine, Vol. 36, Extra Issue, pp. 220-229, (1999)	Partial		

Examiner Signature	Date Considered	

Applicant's unique citation designation number (optional). ²See Kind Codes of USPTO Patent Documents at www.uspto.gov, MPEP 901.04 or in the comment box of this document. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST. 3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to indicate here if English language Translation is attached.

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.